JHVEPhoto / Shutterstock.com

25 September 2025NewsEuropeLiz Hockley

EU court delivers verdict on Biogen’s market exclusivity for MS drug

The General Court has handed a win to generic drug makers including Teva and Mylan in the battle over multiple sclerosis drug Tecfidera.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

More features

Budgets, CRISPR, and keeping pace with tech: top challenges for Europe’s patent pros

Mewburn expands AI and medtech expertise with Munich hire

AbbVie faces secrets lawsuit over $2.1bn Capstan deal

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

Scientist jumps from Jones Day to expand rival’s biotech offering

AIPPI: Personalised medicine tests the limits in patent law